




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07D 213/30, A61K 31/44	A1	(11) International Publication Number: WO 95/35285 (43) International Publication Date: 28 December 1995 (28.12.95)
(21) International Application Number: PCT/GB95/01467 (22) International Filing Date: 22 June 1995 (22.06.95) (30) Priority Data: 9412571.3 22 June 1994 (22.06.94) GB (71) Applicant: CELLTECH THERAPEUTICS LIMITED [GB/GB]; 216 Bath Road, Slough, Berkshire SL1 4EN (GB). (72) Inventors: ALEXANDER, Rikki, Peter; 14 Carrington Road, High Wycombe, Bucks HP12 3HY (GB). WARRELOW, Graham, John; Oakside, 4 Wieland Road, Northwood, Middlesex HA6 3QU (GB). (74) Agent: SKAILES, Humphrey, John; Frank B. Dehn & Co., Imperial House, 15-19 Kingsway, London WC2B 6UZ (GB).		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG). Published <i>With international search report.</i>

(54) Title: TETRA-SUBSTITUTED PHENYL DERIVATIVES USEFUL AS PDE IV INHIBITORS**(57) Abstract**

Compounds of general formula (1) are described wherein =W- is 1) -C(Y)- where Y is a halogen atom, or an alkyl, or -X^aR¹ group where X^a is -O-, -S(O)_m- [where m is zero or an integer of value 1 or 2], or -N(R^a)- [where R^a is a hydrogen atom or an optionally substituted alkyl group] and R¹ is a hydrogen atom or an optionally substituted alkyl group or, 2) =N-; X is as described above for X^a or is a chain -CR=C(R^b)- or [-CH(R)]_q-CH(R^b)- where R is a hydrogen or a fluorine atom or a methyl group, R^b is as described below for R² and q is zero or the integer 1; R² is 1) an optionally substituted alkyl, alkenyl, cycloalkyl or cycloalkenyl group when X is -O-, -S(O)_m- or -N(R^a)-; or is 2) when X is other than -O-, -S(O)_m- or -N(R^a)-, a hydrogen atom, or an optionally substituted straight or branched alkyl, alkenyl or alkynyl, alkoxy, alkylthio, -CO₂R⁹ (where R⁹ is a hydrogen atom or an optionally substituted alkyl, aryl or aralkyl group), -CONR¹⁰R¹¹ (where R¹⁰ and R¹¹ which may be the same or different is as described for R⁹), -CSNR¹⁰R¹¹, -CN or NO₂ group; or R² and R^b, together with the carbon atom to which they are both attached, are linked to form an optionally substituted cycloalkyl or cycloalkenyl group optionally containing one or more X^a atoms or groups; R³ is an atom or group R¹³ or -L¹R¹³ where L¹ is a linker group and R¹³ is various substituents; R⁴ is a hydrogen atom or is as defined for R⁶; R⁵ is a hydrogen or a fluorine atom, or an OR^c group where R^c is a hydrogen atom or an optionally substituted straight or branched alkyl, alkenyl, alkoxyalkyl, alkanoyl, formyl, carboxamido, thiocarboxamido, cycloalkyl, or cycloalkenyl group; R⁶ is a group -(CH₂)_nAr where Ar is an optionally substituted monocyclic or bicyclic aryl ring optionally interrupted by one or more heteroatoms -O-, -S- or -N- and n is zero or the integer 1, 2 or 3; R⁷ and R⁸, which may be the same or different, is a hydrogen or a fluorine atom, or an optionally substituted straight or branched alkyl group; and the salts, solvates, prodrugs, hydrates and N-oxides thereof. Compounds according to the invention are phosphodiesterase type IV inhibitors and are useful in the prophylaxis and treatment of disease such as asthma where an unwanted inflammatory response or muscular spasm is present.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LJ	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

TETRA-SUBSTITUTED PHENYL DERIVATIVES USEFUL AS PDE IV INHIBITORS

- 5 This invention relates to a novel series of tetra-substituted phenyl derivatives, to processes for their preparation, to pharmaceutical compositions containing them, and to their use in medicine.

10 Many hormones and neurotransmitters modulate tissue function by elevating intra-cellular levels of adenosine 3', 5'-cyclic monophosphate (cAMP). The cellular levels of cAMP are regulated by mechanisms which control synthesis and breakdown. The synthesis of cAMP is controlled by adenylyl cyclase which may be directly activated by agents such as forskolin or indirectly activated by the binding of specific agonists to cell surface
15 receptors which are coupled to adenylyl cyclase. The breakdown of cAMP is controlled by a family of phosphodiesterase (PDE) isoenzymes, which also control the breakdown of guanosine 3',5'-cyclic monophosphate (cGMP). To date, seven members of the family have been described (PDE I-VII) the distribution of which varies from tissue to tissue. This
20 suggests that specific inhibitors of PDE isoenzymes could achieve differential elevation of cAMP in different tissues, [for reviews of PDE distribution, structure, function and regulation, see Beavo & Reifsnnyder (1990) TIPS, 11: 150-155 and Nicholson et al (1991) TIPS, 12: 19-27].

- 25 There is clear evidence that elevation of cAMP in inflammatory leukocytes leads to inhibition of their activation. Furthermore, elevation of cAMP in airway smooth muscle has a spasmolytic effect. In these tissues, PDE IV plays a major role in the hydrolysis of cAMP. It can be expected, therefore, that selective inhibitors of PDE IV would have therapeutic
30 effects in inflammatory diseases such as asthma, by achieving both anti-inflammatory and bronchodilator effects.


35 The design of PDE IV inhibitors has met with limited success to date, in that many of the potential PDE IV inhibitors which have been synthesised have lacked potency and/or have been capable of inhibiting more than one type of PDE isoenzyme in a non-selective manner. Lack of a selective

action has been a particular problem given the widespread role of cAMP in vivo and what is needed are potent selective PDE IV inhibitors with an inhibitory action against PDE IV and little or no action against other PDE isoenzymes.

5

We have now found a novel series of tetra-substituted phenyl derivatives, members of which are potent inhibitors of PDE IV at concentrations at which they have little or no inhibitory action on other PDE isoenzymes. These compounds inhibit the human recombinant PDE IV enzyme and
 10 also elevate cAMP in isolated leukocytes. The compounds of the invention are therefore of use in medicine, especially in the prophylaxis and treatment of asthma.

Thus according to one aspect of the invention, we provide a compound of
 15 formula (1)



wherein

=W- is (1) =C(Y)- where Y is a halogen atom, or an alkyl, or -X^aR¹ group
 20 where X^a is -O-, -S(O)_m- [where m is zero or an integer of value 1 or 2], or
 -N(R^a)- [where R^a is a hydrogen atom or an optionally substituted alkyl
 group] and R¹ is an optionally substituted alkyl group or, (2) =N-;
 X is as described above for X^a or is a chain -CR=C(R^b)- or -[CH(R)]_q-
 CH(R^b)- where R is a hydrogen or a fluorine atom or a methyl group, R^b is
 25 as described below for R² and q is zero or the integer 1;
 R² is (1) an optionally substituted alkyl, alkenyl, cycloalkyl or cycloalkenyl
 group when X is -O-, -S(O)_m- or -N(R^a)-; or when X is -CR=C(R^b)- or
 -[CH(R)]_qCH(R^b)- is (2) a hydrogen atom, or an optionally substituted
 straight or branched alkyl, alkenyl or alkynyl, alkoxy, alkylthio, -CO₂R⁹
 30 (where R⁹ is a hydrogen atom or an optionally substituted alkyl, aryl or
 aralkyl group), -CONR¹⁰R¹¹ (where R¹⁰ and R¹¹ which may be the same
 or different is as described for R⁹), -CSNR¹⁰R¹¹, -CN or NO₂ group; or R²

and R^b, together with the carbon atom to which they are both attached, are linked to form an optionally substituted cycloalkyl or cycloalkenyl group optionally containing one or more X^a atoms or groups;

- R³ is an atom or group R¹³ or -L¹R¹³ where L¹ is a linker group and R¹³ is a halogen atom or an Alk¹ [where Alk¹ is an optionally substituted straight or branched C₁₋₆ alkyl, C₂₋₆alkenyl or C₂₋₆alkynyl group optionally interrupted by one, two, or three -O-, or -S- atoms or -S(O)p-, [where p is an integer 1 or 2], or -N(R^a)- groups], or an amino (-NH₂), substituted amino, nitro, cyano, hydroxyl (-OH), substituted hydroxyl, cycloalkyl, cycloalkoxy, formyl [HC(O)-], carboxyl (-CO₂H), esterified carboxyl, thiol (-SH), substituted thiol, -C(O)Alk¹, -SO₃H, -SO₂Alk¹, -SO₂NH₂, -SO₂NHAlk¹, -SO₂N[Alk¹]₂, -SO₂NHAr [where Ar is as defined below for R⁶], -SO₂N(Alk¹)Ar, -CONH₂, -CONHAlk¹, -CON[Alk¹]₂, -CONHAr, -CON(Alk¹)Ar, -NHSO₂H, -NAlk¹SO₂H, -NHSO₂Alk¹, -NAlk¹SO₂Alk¹, -N[SO₂Alk¹]₂, -N(Alk¹)SO₂N(Alk¹)Ar, -NHSO₂NH₂, -N(Alk¹)SO₂NH₂, -NHSO₂NHAlk¹, -N(Alk¹)SO₂NHAlk¹, -NHHSO₂N[Alk¹]₂, -NAlk¹SO₂N[Alk¹]₂, -NHSO₂NHAr, -N(Alk¹)SO₂NHAr, -NHSO₂N(Alk¹)Ar, -N(Alk¹)SO₂N(Alk¹)Ar, -NHC(O)Alk¹, -N(Alk¹)C(O)Alk¹, -N[C(O)Alk¹]₂, -NHC(O)OAlk¹, -N(Alk¹)C(O)OAlk¹, -Ar, -Het [where Het is a C₅₋₇ heterocycloalkyl group], -CONHet¹ [where -NHet¹ is a C₅₋₇ cycloamino group optionally containing one or more -O- or -S- atoms or -N(R^a)- groups], -SO₂NHet¹, -NHSO₂NHet¹, -CSAlk¹, -CSNH₂, -CSNHAlk¹, -CSN[Alk¹]₂, -CSNHAr, -CSN(Alk¹)Ar, -NHC(S)Alk¹, -N(Alk¹)C(S)Alk¹, -CSNHet¹ group, -N[C(S)Alk¹]₂, -N[C(O)Alk¹]SO₂Alk¹, -N[C(S)Alk¹]SO₂Alk¹, -NHC(O)NH₂, -NHC(O)NHAlk¹, -NHC(O)N[Alk¹]₂, -N(Alk¹)CONH₂, -N(Alk¹)C(O)NHAlk¹, -N(Alk¹)C(O)N[Alk¹]₂, -NHC(S)NH₂, -NHC(S)NHAlk¹, -NHC(S)N[Alk¹]₂, -N(Alk¹)CSNH₂, -N(Alk¹)C(S)NHAlk¹, or -N(Alk¹)C(S)N[Alk¹]₂ group;

R⁴ is a hydrogen atom or is as defined for R⁶;

- R⁵ is a hydrogen or a fluorine atom, or an OR^c group where R^c is a hydrogen atom or an optionally substituted straight or branched alkyl, alkenyl, alkoxyalkyl, alkanoyl, formyl, carboxamido, thiocarboxamido, cycloalkyl, or cycloalkenyl group;

- R⁶ is a group -(CH₂)_nAr where Ar is an optionally substituted monocyclic or bicyclic aryl ring optionally interrupted by one or more heteroatoms -O-, -S- or -N- and n is zero or the integer 1, 2 or 3;

R⁷ and R⁸, which may be the same or different, is a hydrogen or a fluorine atom, or an optionally substituted straight or branched alkyl group; and the salts, solvates, prodrugs, hydrates and N-oxides thereof.

5 It will be appreciated that compounds of formula (1) may have one or more chiral centres depending on the nature of the groups X, R, R³, R⁴, R⁵, R⁶, and R⁷. Where one or more chiral centres is present, enantiomers or diastereomers may exist, and the invention is to be understood to extend to all such enantiomers, diastereomers and mixtures thereof, including
10 racemates.

Compounds of formula (1) where X is a chain -CR=C(R^b)- may exist as geometric isomers depending on the nature of the groups R, R^b and R², and the invention is to be understood to extend to all such isomers and
15 mixtures thereof.

In the compounds of formula (1), when Y is a halogen atom it may be for example a fluorine, chlorine, bromine or iodine atom.

20 When =W- in the compounds of formula (1) is a group =C(Y)- where Y is a group -X^aR¹, R¹ may be, for example, an optionally substituted straight or branched alkyl group, for example, an optionally substituted C₁₋₆alkyl group, such as a methyl, ethyl, n-propyl or i-propyl group. Optional substituents which may be present on R¹ groups include one or more
25 halogen atoms, e.g. fluorine, or chlorine atoms. Particular R¹ groups include for example -CH₂F, -CH₂Cl, -CHF₂, -CHCl₂, -CF₃ or -CCl₃ groups.

When =W- in compounds of formula (1) is a group =C(Y)- where Y is X^aR¹ in which X^a is a -N(R^a)- group, X^a may be a -NH-, -NCH₂- or -NC₂H₄-
30 group.

Alkyl groups represented by R¹, R², R⁶, R⁷, or R⁸ in compounds of formula (1) include optionally substituted straight or branched C₁₋₆ alkyl groups, e.g. C₁₋₃ alkyl groups such as methyl or ethyl groups. Optional
35 substituents on these groups include one, two or three substituents selected from halogen atoms, e.g. fluorine, chlorine, bromine or iodine

atoms, or hydroxyl or C₁₋₆ alkoxy e.g. C₁₋₃ alkoxy such as methoxy or ethoxy groups.

- Alkenyl groups represented by R², or R^c in compounds of formula (1)
- 5 include optionally substituted straight or branched C₂₋₆alkenyl groups such as ethenyl, propen-1-yl and 2-methylpropen-1-yl. Optional substituents include those described above in relation to the alkyl groups represented by R².
- 10 Alkynyl groups represented by R², or R^b in compounds of formula (1) include optionally substituted straight or branched C₂₋₆alkynyl groups optionally interrupted by one or more X^a atoms or groups. Particular examples include ethynyl and propyn-1-yl groups. Optional substituents include those described above in relation to alkyl groups represented by
- 15 R².

- When R², or R^b or R² and R^b, together with the carbon atom to which they are both attached, are an optionally substituted cycloalkyl or cycloalkenyl group the group may be for example a C₃₋₈cycloalkyl group such as a
- 20 cyclobutyl, cyclopentyl or cyclohexyl group or a C₃₋₈ cycloalkenyl group containing for example one or two double bonds such as a 2-cyclobuten-1-yl, 2-cyclopenten-1-yl, 3-cyclopenten-1-yl, 2,4-cyclopentadien-1-yl, 2-cyclohexen-1-yl, 3-cyclohexen-1-yl, 2,4-cyclohexadien-1-yl or 3,5-cyclohexadien-1-yl group, each cycloalkyl or cycloalkenyl group being
- 25 optionally substituted by one, two or three substituents selected from halogen atoms, e.g. fluorine, chlorine, bromine or iodine atoms, straight or branched C₁₋₆alkyl e.g. C₁₋₃alkyl such as methyl or ethyl, hydroxyl or C₁₋₆alkoxy e.g. C₁₋₃alkoxy such as methoxy or ethoxy groups.

- 30 When the group =W- in compounds of formula (1) is a group =C(Y)- in which Y is a halogen atom Y may be for example a fluorine, chlorine, bromine or iodine atom.

- Particular examples of -(CH₂)_nAr groups represented by R⁴ and/or R⁶
- 35 include -Ar, -CH₂Ar, -(CH₂)₂Ar or -(CH₂)₃Ar groups.

Monocyclic or bicyclic aryl groups represented by the group Ar in compounds of formula (1) include for example C₆₋₁₂ optionally substituted aryl groups, for example optionally substituted phenyl, 1-or 2-naphthyl, indenyl or isoindenyl groups.

5

When the monocyclic or bicyclic aryl group Ar contains one or more heteroatoms it may be for example a C₁₋₉ optionally substituted heteroaryl group containing for example one, two, three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms. In general, Ar heteroaryl groups may be for example monocyclic or bicyclic heteroaryl groups. Monocyclic heteroaryl groups include for example five- or six-membered heteroaryl groups containing one, two, three or four heteroatoms selected from oxygen or sulphur atoms or a group -N(Ra)-.

15

Examples of heteroaryl groups represented by Ar include pyrrolyl, furyl, thienyl, imidazolyl, N-methylimidazolyl, N-ethylimidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, 1,3,5-triazinyl, 1,2,4-triazinyl, 1,2,3-triazinyl, benzofuryl, isobenzofuryl, benzothienyl, isobenzothienyl, indolyl, isoindolyl, benzimidazolyl, benzothiazolyl, benzoxazolyl, quinazolinyl, naphthyridinyl, pyrido[3,4-b]pyridyl, pyrido[3,2-b]pyridyl, pyrido[4,3-b]pyridyl, quinolinyl, isoquinolinyl, tetrazolyl, 5,6,7,8-tetrahydroquinolinyl and 5,6,7,8-tetrahydroisoquinolinyl.

25

The heteroaryl group represented by Ar may be attached to the remainder of the molecule of formula (1) through any ring carbon or heteroatom as appropriate. Thus, for example, when the group Ar is a pyridyl group it may be a 2-pyridyl, 3-pyridyl or 4-pyridyl group. When it is a thienyl group it may be a 2-thienyl or 3-thienyl group, and, similarly, when it is a furyl group it may be a 2-furyl or 3-furyl group.

30

When in compounds of formula (1) the Ar group is a nitrogen-containing heterocycle it may be possible to form quaternary salts, for example N-alkyl quaternary salts and the invention is to be understood to extend to such salts. Thus for example when the group Ar is a pyridyl group,

35

pyridinium salts may be formed, for example N-alkylpyridinium salts such as N-methylpyridinium.

5 The aryl or heteroaryl groups represented by Ar in compounds of formula (1) may each optionally be substituted by one, two, three or more R¹³ substituents.

10 When R¹³ in compounds of formula (1) is a substituted amino group it may be a group -NH[Alk¹(R^{13a})_z] [where z is zero or an integer 1, 2 or 3 and R^{13a} is as defined above for R¹³ but is not a substituted amino, a substituted hydroxyl or a substituted thiol group] or a group -N[Alk¹(R^{13a})_z]₂ wherein each -Alk¹(R^{13a})_z group is the same or different.

15 When R¹³ is a cycloalkoxy group it may be for example a C₅₋₇cycloalkoxy group such as a cyclopentyloxy or cyclohexyloxy group.

When R¹³ is a substituted hydroxyl or substituted thiol group it may be a group -OAlk¹(R^{13a})_z or -SAlk¹(R^{13a})_z respectively, where Alk¹, R^{13a} and z are as just defined.

20

Esterified carboxyl groups represented by the group R¹³ include groups of formula -CO₂Alk² wherein Alk² is a straight or branched, optionally substituted C₁₋₈alkyl group such as a methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl or t-butyl group; a C₆₋₁₂arylC₁₋₈alkyl group such as an optionally substituted benzyl, phenylethyl, phenylpropyl, 1-naphthylmethyl or 2-naphthylmethyl group; a C₆₋₁₂aryl group such as an optionally substituted phenyl, 1-naphthyl or 2-naphthyl group; a C₆₋₁₂aryloxyC₁₋₈alkyl group such as an optionally substituted phenyloxymethyl, phenyloxyethyl, 1-naphthyloxymethyl, or 2-naphthyloxymethyl group; an optionally substituted C₁₋₈alkanoyloxyC₁₋₈alkyl group, such as a pivaloyloxymethyl, propionyloxyethyl or propionyloxypropyl group; or a C₆₋₁₂aroyloxyC₁₋₈alkyl group such as an optionally substituted benzoyloxyethyl or benzoyloxypropyl group. Optional substituents present on the Alk² group include R¹³ substituents described above.

35

- Particular examples of -Het groups represented by the group R¹³ include optionally substituted pyrrolyl, e.g. 2H-pyrrolyl, pyrrolinyl, e.g. 2- or 3-pyrrolinyl, pyrrolidinyl, 1,3-dioxolanyl, imidazolinyl, e.g. 2-imidazolinyl, imidazolidinyl, pyrazolinyl, e.g. 2-pyrazolinyl, pyrazolidinyl, pyranyl, e.g. 2- or 4-pyranyl, piperidinyl, 1,4-dioxanyl, morpholinyl, 1,4-dithianyl, thiomorpholinyl, piperazinyl, 1,3,5-trithianyl, 3H-pyrrolyl, 2H-imidazolyl, dithiolyl, e.g. 1, 2- or 1,3-dithiolyl, oxathiolyl, e.g. 3H-1,2 or 1,3-oxathiolyl, 5H-1,2,5-oxathiazolyl, 1,3-dioxinyl, oxazinyl, e.g. 2H-1,3-, 6H-1,3-, 6H-1,2-, 1,4-2H-1,2- or 4H-1,4-oxazinyl, 1,2,5-oxathiazinyl, isoxazinyl, e.g. -o- or p-isoxazinyl, oxathiazinyl, e.g. 1,2,5-, 1,2,6-oxathiazinyl, 1,3,5,2-oxadiazinyl, or 1,2,4-diazepinyl groups. Optional substituents which may be present on such groups include those substituents discussed above in relation to the alkyl groups represented by R¹, R², R⁶, R⁷ or R⁸.
- Examples of the group Alk¹ in compounds of formula (1) include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, ethenyl, 2-propenyl, 2-butenyl, 3-butenyl, ethynyl, 2-propynyl, 2-butyryl or 3-butyryl groups optionally interrupted by one, two or three -O- or -S- atoms or -S(O)-, -S(O)₂- or -N(R^a)- groups.
- Particularly useful atoms or groups represented by R¹³ include fluorine, chlorine, bromine or iodine atoms, or C₁₋₆alkyl, e.g. methyl or ethyl, C₁₋₆alkylamino, e.g. methylamino or ethylamino, C₁₋₆ hydroxyalkyl, e.g. hydroxymethyl or hydroxyethyl, C₁₋₆alkylthiol e.g. methylthiol or ethylthiol, C₁₋₆alkoxy, e.g. methoxy or ethoxy, C₅₋₇ cycloalkyl, e.g. cyclopentyl, C₅₋₇ cycloalkoxy, e.g. cyclopentyloxy, haloC₁₋₆alkyl, e.g. trifluoromethyl, C₁₋₆alkylamino, e.g. methylamino or ethylamino, amino (-NH₂), aminoC₁₋₆ alkyl, e.g. aminomethyl or aminoethyl, C₁₋₆dialkylamino, e.g. dimethylamino or diethylamino, nitro, cyano, hydroxyl (-OH), formyl [HC(O)-], carboxyl (-CO₂H), -CO₂Alk² [where Alk² is as defined above], C₁₋₆alkanoyl e.g. acetyl, thiol (-SH), thioC₁₋₆alkyl, e.g. thiomethyl or thioethyl, optionally substituted phenyl or naphthyl (where the optional substituents are selected from one or more atoms or groups R¹³ or L¹R¹³), a group -Het as just described above, sulphonyl (-SO₃H), C₁₋₆ alkylsulphonyl, e.g. methylsulphonyl, aminosulphonyl (-SO₂NH₂), C₁₋₆ alkylaminosulphonyl, e.g. methylaminosulphonyl or ethylaminosulphonyl, C₁₋₆dialkylaminosulphonyl,

- e.g. dimethylaminosulphonyl or diethylaminosulphonyl, phenylamino-sulphonyl, carboxamido (-CONH₂), C₁₋₆alkylaminocarbonyl, e.g. methylaminocarbonyl or ethylaminocarbonyl, C₁₋₆ dialkylaminocarbonyl, e.g. dimethylaminocarbonyl or diethylaminocarbonyl, phenylaminocarbonyl,
- 5 sulphonylamino (-NHSO₂H), C₁₋₆ alkylsulphonylamino, e.g. methylsulphonylamino or ethylsulphonylamino, C₁₋₆dialkylsulphonylamino, e.g. dimethylsulphonylamino or diethylsulphonylamino, aminosulphonylamino (-NHSO₂NH₂), C₁₋₆alkylaminosulphonylamino, e.g. methylaminosulphonylamino or ethylaminosulphonylamino, C₁₋₆dialkylaminosulphonylamino, e.g.
- 10 dimethylaminosulphonylamino or diethylaminosulphonylamino, phenylaminosulphonylamino, C₁₋₆ alkanoylamino, e.g. acetylamino, C₁₋₆alkanoylamino, C₁₋₆alkyl, e.g. acetylaminomethyl or C₁₋₆alkoxycarbonylamino, e.g. methoxycarbonylamino, ethoxycarbonylamino, or t-butoxycarbonylamino, thiocarboxamido (-CSNH₂), C₁₋₆ alkylaminothiocarbonyl, e.g.
- 15 methylaminothiocarbonyl or ethylaminothiocarbonyl, C₁₋₆dialkylaminothiocarbonyl, e.g. dimethylaminothiocarbonyl or diethylaminothiocarbonyl, phenylaminothiocarbonyl, aminocarbonylamino, C₁₋₆alkylaminocarbonylamino, e.g. methylaminocarbonylamino or ethylaminocarbonylamino, C₁₋₆dialkylaminocarbonylamino, e.g. dimethylaminocarbonylamino or diethylaminocarbonylamino, aminothiocarbonylamino, C₁₋₆alkylaminothiocarbonylamino, e.g. methylaminothiocarbonylamino or ethylaminothiocarbonylamino, C₁₋₆ dialkylaminothiocarbonylamino, e.g. dimethylaminothiocarbonylamino, or diethylaminothiocarbonylamino, aminocarbonylC₁₋₆alkylamino, e.g. aminocarbonylmethylamino or aminocarbonylethylamino,
- 20 aminothiocarbonylC₁₋₆alkylamino e.g. aminothiocarbonylmethylamino or aminothiocarbonylethylamino, formylaminoC₁₋₆ alkylsulphonylamino, e.g. formylaminomethylsulphonylamino or formylaminoethylsulphonylamino, thioformylaminoC₁₋₆alkylsulphonylamino, e.g. thioformylaminomethylsulphonylamino or thioformylethylsulphonylamino, C₁₋₆acylamino-sulphonylamino, e.g. acetylaminosulphonylamino, C₁₋₆thioacylamino-sulphonylamino, e.g. thioacetylaminosulphonylamino groups.
- 30

In the compounds of formula (1), when R³ is a L¹R¹³ group the linker group L¹ may be any divalent linking group. Particular examples of L¹ groups

35 include groups of formula -(Alk^a)_r(X^a)_s(Alk^b)_t- where Alk^a and Alk^b is each an optionally substituted straight or branched C₁₋₆alkylene, C₂₋₆alkenylene or

C₂₋₆alkynylene chain optionally interrupted by one or more, e.g. one, two or three heteroatoms or carbocyclic or heteroatom-containing groups, X^a is an -O- or -S- atom or a -S(O)-, -S(O)₂- or -N(R^b)- group, r is zero or the integer 1, t is zero or the integer 1 and s is zero or the integer 1, provided that when one of r, s, or t is zero at least one of the remainder is the integer 1.

The heteroatoms which may interrupt the Alk^a or Alk^b chains include for example -O- or -S- atoms. Carbocyclic groups include for example cycloalkyl, e.g. cyclopentyl or cyclohexyl, or cycloalkenyl e.g. cyclopentenyl or cyclohexenyl, groups. Particular heteroatom-containing groups which may interrupt Alk^a or Alk^b include oxygen-, sulphur- or nitrogen-containing groups such as -S(O)-, -S(O)₂-, -N(R^b)-, -C(O)-, -C(S)-, -C(NR^b)-, -CON(R^b)-, -CSN(R^b)-, -N(R^b)CO-, -N(R^b)CS-, -SON(R^b)-, -SO₂N(R^b)-, -N(R^b)SO-, -N(R^b)SO₂-, -N(R^b)SO₂N(R^b)-, -N(R^b)SON(R^b)-, -N(R^b)CON(R^b)-, or N(R^b)CSN(R^b)- groups. It will be appreciated that when the chains Alk^a or Alk^b are interrupted by two or more heteroatoms, carbocyclic or heteroatom-containing groups, such atoms or groups may be adjacent to one another, for example to form a group -N(R^b)-C(NR^b)-N(R^b)- or -O-CONH-.

Optional substituents which may be present on Alk^a or Alk^b chains include those described above in relation to the group R¹ when it is an alkyl group.

In the group -L¹R¹³ particular examples of Alk^a or Alk^b when present include optionally substituted methylene, ethylene, propylene, butylene, ethenylene, 2-propenylene, 2-butenylene, 3-butenylene, ethynylene, 2-propynylene, 2-butyne, or 3-butyne chains, optionally interrupted by one, two or three heteroatoms, carbocyclic or heteroatom-containing groups as described above.

Particular groups represented by -L¹R¹³ include for example -CH₂Ar, -(CH₂)₂Ar, -CH=CHAr, -(CH₂)₃Ar, -CH₂CH=CHAr, -OCH₂Ar, -CH₂OAr, -CH₂OCH₂Ar, -CH₂N(R^a)Ar or -CH₂N(R^a)CH₂Ar groups.

The group R^3 in compounds of formula (1) may in general be attached to the remainder of the molecule through a carbon atom adjacent to the group $-C(R^4)(R^5)C(R^6)(R^7)(R^8)$ or the group W.

- 5 The presence of certain substituents in the compounds of formula (1) may enable salts of the compounds to be formed. Suitable salts include pharmaceutically acceptable salts, for example acid addition salts derived from inorganic or organic acids, and salts derived from inorganic and organic bases.

10

Acid addition salts include hydrochlorides, hydrobromides, hydroiodides, alkylsulphonates, e.g. methanesulphonates, ethanesulphonates, or isethionates, arylsulphonates, e.g. p-toluenesulphonates, besylates or napsylates, phosphates, sulphates, hydrogen sulphates, acetates, trifluoroacetates, propionates, citrates, maleates, fumarates, malonates, succinates, lactates, oxalates, tartrates and benzoates.

15

Salts derived from inorganic or organic bases include alkali metal salts such as sodium or potassium salts, alkaline earth metal salts such as magnesium or calcium salts, and organic amine salts such as morpholine, piperidine, dimethylamine or diethylamine salts.

20

Particularly useful salts of compounds according to the invention include pharmaceutically acceptable salts, especially acid addition pharmaceutically acceptable salts.


25

In compounds of formula (1), the group $=W-$ is preferably a $=C(Y)-$ group in which Y is an $-OR^1$ group, especially where R^1 is an optionally substituted ethyl group, or an optionally substituted methyl group. Especially useful substituents which may be present on R^1 groups include one, two or three fluorine or chlorine atoms.

30

The group X in compounds of formula (1) is preferably $-O-$.

- 35 Particularly useful groups of compounds of formula (1) have the formula (2)



(2)

5 where R² is an optionally substituted cycloalkyl group; R³, R⁴, R⁵, R⁶, R⁷ and R⁸ are as defined for formula (1); and the salts, solvates, hydrates, prodrugs and N-oxides thereof.

10 In the compounds of formulae (1) and (2), R² is preferably an optionally substituted methyl or cyclopentyl group. In particular R² is a cyclopentyl group.

15 In the compounds of formulae (1) and (2) R⁴ is preferably a hydrogen atom or an -Ar or -CH₂Ar group, where Ar is an optionally substituted aryl or heteroaryl group, particularly a phenyl or nitrogen containing heteroaryl group such as a pyridyl group. In general however in compounds of formulae (1) and (2) R⁴ is especially a hydrogen atom.

20 The groups R⁵, R⁷ and R⁸ in compounds of formulae (1) and (2) is each preferably a fluorine atom or especially a hydrogen atom.

25 In the compounds of formulae (1) and (2) the group R⁶ is preferably an -Ar group, especially a nitrogen containing monocyclic heteroaryl group. Particularly useful groups of this type are optionally substituted pyridyl groups, particularly optionally substituted 4-pyridyl groups.

30 In the compounds of formulae (1) and (2) R³ is preferably a halogen atom or an optionally substituted C₁₋₆alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₆₋₁₂ mono- or bicyclic aryl, arC₁₋₃alkyl or arC₁₋₃alkenyl, or C₁₋₉ mono- or bicyclic heteroaryl or heteroarC₁₋₃alkyl group. Optional substituents which may be present on these groups include, for alkyl, alkenyl or alkynyl groups, those substituents described above in relation to the group R¹,

and for aryl, aralkyl, heteroaryl or heteroaralkyl groups, R¹³ substituents as described above.

5 Particular examples of aryl or aralkyl groups include optionally substituted phenyl, naphthyl, phenC₁₋₃alkyl or naphthylC₁₋₃alkyl groups. Examples of heteroaryl or heteroaralkyl groups include optionally substituted pyridyl or pyridylC₁₋₃alkyl groups.

10 Particular examples of R³ in the compounds of formulae (1) and (2) include bromine, chlorine or iodine atoms or, methyl, ethyl, ethenyl 2-propenyl, ethynyl, 2-propynyl, phenyl, naphthyl, benzyl, phenylethyl, phenylethenyl, phenylpropen-1-yl, phenylpropen-2-yl, 2-, 3- or 4-pyridyl, 2-, 3- or 4- pyridylmethyl, or 2-, 3- or 4-pyridylethyl, each of said phenyl or pyridyl groups being optionally substituted by one or more R¹³ substituents.

15 The group R³ may in particular be positioned on one of the two ring carbon atoms between the group W and the group -C(R⁴)(R⁵)C(R⁶)(R⁷)(R⁸) either adjacent to the group W or adjacent to the group -C(R⁴)(R⁵)C(R⁶)(R⁷)(R⁸).

Particularly useful compounds according to the invention are:
4-[2-(5-Cyclopentyloxy-2-iodo-4-methoxyphenyl)ethyl]pyridine;
4-[2-(5-Cyclopentyloxy-4-methoxy-2-phenyl)ethyl]pyridine;
25 4-[2-[5-Cyclopentyloxy-4-methoxy-2-(2-phenylethenyl)phenyl]ethyl]pyridine;
4-[2-[5-Cyclopentyloxy-4-methoxy-2-(2-phenylethyl)phenyl]ethyl] pyridine;
4-[2-[5-Cyclopentyloxy-4-methoxy-2-(1-naphthyl)phenyl]ethyl} pyridine;
4-[2-[5-Cyclopentyloxy-4-methoxy-2-(2-naphthyl)phenyl]ethyl} pyridine;
30 4-[2-[5-Cyclopentyloxy-4-methoxy-2-(3-pyridyl)phenyl]ethyl}pyridine;
or each isomer and enantiomer, and/or the salts, hydrates, solvates, prodrugs and N-oxides thereof.

35 Compounds according to the invention are selective and potent inhibitors of PDE IV. The ability of the compounds to act in this way may be simply determined by the tests described in the Examples hereinafter.

5 The compounds according to the invention are thus of particular use in the prophylaxis and treatment of human diseases where an unwanted inflammatory response or muscular spasm (for example bladder or alimentary smooth muscle spasm) is present and where the elevation of cAMP levels may be expected to prevent or alleviate the inflammation and relax muscle.

10 Particular uses to which the compounds of the invention may be put include the prophylaxis and treatment of asthma, especially inflamed lung associated with asthma, cystic fibrosis, or in the treatment of inflammatory airway disease, chronic bronchitis, eosinophilic granuloma, psoriasis and other benign and malignant proliferative skin diseases, endotoxic shock, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the
15 myocardium and brain, inflammatory arthritis, chronic glomerulonephritis, atopic dermatitis, urticaria, adult respiratory distress syndrome, diabetes insipidus, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, arterial restenosis and atherosclerosis.

20 Compounds of the invention also suppress neurogenic inflammation through elevation of cAMP in sensory neurones. They are, therefore, analgesic, anti-tussive and anti-hyperalgesic in inflammatory diseases associated with irritation and pain.

25 Compounds according to the invention may also elevate cAMP in lymphocytes and thereby suppress unwanted lymphocyte activation in immune-based diseases such as rheumatoid arthritis, ankylosing spondylitis, transplant rejection and graft versus host disease.

30 Compounds according to the invention have also been found to reduce gastric acid secretion and therefore can be used to treat conditions associated with hypersecretion.

35 Compounds of the invention suppress cytokine synthesis by inflammatory cells in response to immune or infectious stimulation. They are, therefore, useful in the treatment of bacterial, fungal or viral induced sepsis and

septic shock in which cytokines such as tumour necrosis factor (TNF) are key mediators. Also compounds of the invention suppress inflammation and pyrexia due to cytokines and are, therefore, useful in the treatment of inflammation and cytokine-mediated chronic tissue degeneration which occurs in diseases such as rheumatoid or osteoarthritis.

Over-production of cytokines such as TNF in bacterial, fungal or viral infections or in diseases such as cancer, leads to cachexia and muscle wasting. Compounds of the invention ameliorate these symptoms with a consequent enhancement of quality of life.

Compounds of the invention also elevate cAMP in certain areas of the brain and thereby counteract depression and memory impairment.

Compounds of the invention suppress cell proliferation in certain tumour cells and can be used, therefore, to prevent tumour growth and invasion of normal tissues.

For the prophylaxis or treatment of disease the compounds according to the invention may be administered as pharmaceutical compositions, and according to a further aspect of the invention we provide a pharmaceutical composition which comprises a compound of formula (1) together with one or more pharmaceutically acceptable carriers, excipients or diluents.

Pharmaceutical compositions according to the invention may take a form suitable for oral, buccal, parenteral, nasal, topical or rectal administration, or a form suitable for administration by inhalation or insufflation.

For oral administration, the pharmaceutical compositions may take the form of, for example, tablets, lozenges or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium glycollate); or wetting agents (e.g. sodium lauryl sulphate). The tablets

may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations
5 may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents, emulsifying agents, non-aqueous vehicles and preservatives. The preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate.

10 Preparations for oral administration may be suitably formulated to give controlled release of the active compound.

For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner.

15

The compounds of formula (1) may be formulated for parenteral administration by injection e.g. by bolus injection or infusion. Formulations for injection may be presented in unit dosage form, e.g. in glass ampoule or multi dose containers, e.g. glass vials. The compositions for injection
20 may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising, preserving and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.

25

In addition to the formulations described above, the compounds of formula (1) may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation or by intramuscular injection.

30


For nasal administration or administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation for pressurised packs or a nebuliser, with the use of suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other
35 suitable gas or mixture of gases.

The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack or dispensing device may be accompanied by instructions for administration.

The quantity of a compound of the invention required for the prophylaxis or treatment of a particular inflammatory condition will vary depending on the compound chosen, and the condition of the patient to be treated. In general, however, daily dosages may range from around 100ng/kg to 100mg/kg, e.g. around 0.01mg/kg to 40mg/kg body weight for oral or buccal administration, from around 10ng/kg to 50mg/kg body weight for parenteral administration and around 0.05mg to around 1000mg e.g. around 0.5mg to around 1000mg for nasal administration or administration by inhalation or insufflation.


The compounds according to the invention may be prepared by the following processes. The symbols W, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸ and X, when used in the formulae below are to be understood to represent those groups described above in relation to formula (1) unless otherwise indicated. In the reactions described below it may be necessary to protect reactive functional groups, for example hydroxy, amino, thio, carboxy or aldehyde groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice [see, for example, Green, T. W. in "Protective Groups in Organic Synthesis" John Wiley and Sons, 1981.] It may be that deprotection will form the last step in the synthesis of compounds of formula (1).

Thus according to a further aspect of the invention, a compound of formula (1) where R³ is a group -L¹R¹³ may be prepared by a cross-coupling reaction of compound of formula (3)



where Hal is an iodine or bromine atom with a coupling reagent.

- 5 The reaction may be carried out in the presence of a metal catalyst, such as a metal complex catalyst, for example a palladium complex e.g. dichloro-[1,4-bis(diphenylphosphino)ferrocene]palladium, tetrakis(triphenylphosphine)palladium, or palladium (II) acetate, or a nickel complex such as dichloro-[1,3-bis (diphenylphosphino)propane] nickel.
- 10 The coupling reagents include organometallic reagents, such as organo magnesium reagents $R^{13}L^1MgX$, where X is a halogen atom, such as a chlorine or bromine atom, organozinc reagents $R^{13}L^1ZnX$; boronic acid derivatives, for example $R^{13}L^1B(OH)_2$ in the presence of a base, such as a carbonate e.g. sodium carbonate; or an olefin reagent for example $R^{13}L^1CH=CH_2$ in the presence of a phosphine, e.g. tri-*o*-tolylphosphine and a base such as triethylamine.
- 15 The reaction may take place in a solvent, for example an ether, such as diethylether or a cyclic ether, e.g. tetrahydrofuran or dioxane, or a nitrile, e.g. acetonitrile, at a temperature varied from room temperature to an elevated temperature, e.g. 140°C.
- 20 The coupling reagents are either known compounds or may be prepared using reagents and conditions similar to those used for the preparation of the known compounds.
- 25 It is to be understood that compounds of formula (3) are compounds of formula (1) in which R^3 is a halogen atom. Therefore, in a further aspect of the invention compounds of formula (1) wherein R^3 is a halogen atom may be prepared by halogenation of a compound of formula (4)
- 30




5 This reaction is particularly suitable for preparing compounds in which R^3 is a chlorine, bromine or iodine atom. Thus for example bromination and chlorination may be achieved by using bromine or chlorine in the presence of a catalyst, such as a Lewis acid, e.g. $AlBr_3$, $AlCl_3$, or $FeCl_3$ respectively or an organic acid, e.g. acetic acid where necessary in a solvent for example a halogenated hydrocarbon, e.g. dichloromethane.

10 Iodination may be carried out by the use of iodine in the presence of an oxidising agent, such as HNO_3 , HIO_3 or peracetic acid, or salts, such as copper salts, antimony salts e.g. $SbCl_5$ or sulphonates, e.g. silver trifluoromethanesulphonate, where necessary in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane.

15

Intermediates of formula (4) where R^5 is a hydroxyl group may be prepared by reaction of a compound of formula (5)



20 with


- (a) an organometallic reagent $R^6R^7R^8CM$ where M is a metal atom, such as lithium, or a Grignard reagent $R^6R^7R^8MgHal$, where Hal is a halogen atom, e.g. a bromine atom, or
- (b) a compound $R^6R^7R^8CHal$, where Hal is a halogen atom, such as a bromine atom, using a base, such as *t*-butyllithium.

25

Intermediates of formula (4), where R^5 is a fluorine atom may be prepared by reacting an intermediate of formula (4), where R^5 is a hydroxyl group, with a fluorinating reagent, such as diethylaminosulphur trifluoride (DAST),

in a solvent, for example a chlorinated solvent, e.g. dichloromethane, at a low temperature, e.g. around 0°C.


- 5 Ketones of formula (5) may be prepared by oxidation of a corresponding alcohol of formula (6)



using an oxidising agent such as manganese dioxide in a solvent such as dichloromethane at ambient temperature.


10

Alcohols of formula (6) may be prepared by reaction of an aldehyde of formula (7)



- 15 with an organometallic compound, such as organolithium compound R^4Li , or a Grignard reagent R^4MgBr , in a solvent, such as tetrahydrofuran, at a low temperature, e.g. around -50°C to 0°C.

- 20 Aldehydes of formula (7) where $=W-$ is $=C(Y)-$ may be prepared by alkylation of a corresponding compound of formula (8):




- 25 using a compound R^2Hal [where Hal is as previously defined] using the reagents and conditions described hereinafter for the alkylation of intermediates of formula (15).

Intermediates of formula (8) are either known compounds or may be prepared from known starting materials by methods analogous to those used for the preparation of the known compounds.

5

Intermediates of formula (7) wherein =W- is =N- may be prepared from an intermediate of formula (9)



10


by successive oxidation and reduction reactions.

For example a first oxidation of intermediate (9) by SeO_2 or potassium permanganate gives the carboxylic acid derivative. This in turn may be reduced by a reducing agent, for example lithium aluminium hydride to afford the corresponding alcohol, which upon oxidation with manganese dioxide gives the desired intermediate (7).

15

Intermediates of formula (9) may be prepared by reacting a halide of formula (10)

20




where Hal is a halogen atom, e.g. a bromine, chlorine or iodine atom with a compound RXH , where X is -O-, -S- or -NH- in the presence of a base.

25

Bases used in this reaction include hydrides, such as sodium hydride, or organometallic bases, such as butyllithium in a solvent, such as an amide, for example dimethylformamide at a temperature from room temperature to above, e.g. around 80°C .


Intermediates of formula (10) may be prepared by reacting the commercially available amine of formula (11)



(11)

with nitrous acid (made *in situ* by reacting sodium nitrite with an acid, for example sulphuric acid or hydrobromic acid) to produce the diazonium salt. This in turn may be reacted with a haloacid, e.g. hydrobromic, hydrochloride or hydriodic acid if necessary in the presence of the corresponding copper (1) halide for example CuBr or CuI, or halogen, e.g. bromine, chlorine or iodine.

Alternatively ketones of formula (5) may be prepared by reaction of a halide of formula (12)




(12)

[where Hal is a halogen atom such as bromine or chlorine atom] by halogen metal exchange with a base such as n-butyllithium followed by reaction with a nitrile R^4CN , an acid chloride R^4COCl or an ester R^4CO_2Alk (where Alk is an alkyl group, e.g. a methyl group), in a solvent such as tetrahydrofuran at a low temperature, e.g. around $-70^\circ C$, and subsequent treatment with an acid such as hydrochloric acid at e.g. $-20^\circ C$ to ambient temperature.

Halides of formula (12) may be prepared by alkylation of a compound of formula (13):


23



using the reagents and conditions discussed below in relation to the alkylation of intermediates of formula (15).

5

Halides of formula (13) where X is -O- may be prepared by oxidation of an aldehyde of formula (14):




10

using an oxidising agent such as 3-chloroperoxybenzoic acid in a halogenated hydrocarbon such as chloroform at a temperature from around 0°C to room temperature.

15 Aldehydes of formula (14) and halides of formula (13) where X is -S- or -N(R⁸)- are either known compounds or may be prepared from known starting materials by methods analogous to those used for the preparation of the known compounds.

20 Intermediates of formula (5) where X is -O-, -S- or -N(R^a)- may also be prepared by alkylation of a compound of formula (15)




25 using a reagent R²L, where L is a leaving group.

Leaving groups represented by L include halogen atoms such as iodine, chlorine or bromine atoms, or sulphonyloxy groups such as arylsulphonyloxy groups, e.g. p-toluenesulphonyloxy.

- 5 The alkylation reaction may be carried out in the presence of a base, such as a carbonate, e.g. caesium or potassium carbonate, an alkoxide, e.g. potassium t.butoxide, or a hydride, e.g. sodium hydride, in a dipolar aprotic solvent such as an amide, e.g. a substituted amide such as dimethylformamide, or an ether, e.g. a cyclic ether such as tetrahydrofuran, at
10 ambient temperature or above, e.g. around 40°C to 50°C.

Intermediates of formula (15) are known compounds or may be prepared in a manner similar to the preparation of the known compounds.

- 15 In yet another process according to the invention, compounds of formula (1) where R⁸ and R⁵ is each a hydrogen atom may be prepared by hydrogenation of a compound of formula (16)



20

- The hydrogenation may be performed using for example hydrogen in the presence of a catalyst. Suitable catalysts include metals such as platinum or palladium, optionally supported on an inert carrier such as carbon or calcium carbonate; nickel e.g. Raney Nickel, or rhodium. The reaction
25 may be performed in a suitable solvent, for example an alcohol such as methanol or ethanol, an ether such as tetrahydrofuran or dioxane, or an ester such as ethyl acetate, optionally in the presence of a base, for example a tertiary organic base such as triethylamine, at for example ambient temperature.

30

Alternatively, the reaction may be accomplished by transfer hydrogenation using an organic hydrogen donor and a transfer agent. Suitable hydrogen

donors include for example acids, such as formic acid, formates, e.g. ammonium formates, alcohols, such as benzyl alcohol or ethylene glycol, hydrazine, and cycloalkenes such as cyclohexene or cyclohexadiene. The transfer agent may be for example a transition metal, for example

5 palladium or platinum, optionally supported on an inert carrier as discussed above, nickel e.g. Raney nickel, ruthenium, e.g. tris (triphenylphosphine) ruthenium chloride or copper. The reaction may generally be performed at ambient or elevated temperature, optionally in the presence of a solvent, for example an alcohol such as ethanol or an


10 acid such as acetic acid.

Intermediate alkenes of formula (16) may be obtained by reaction of a corresponding aldehyde of formula (5) [where R^4 is a hydrogen atom] using an olefination agent and the reagents and conditions similar to those

15 described below for the production of a compound of formula (1) from an intermediate of formula (19).

In another process according to the invention, a compound of formula (1) where X is -O-, -S- or -N(R^a)- may be prepared by alkylation of a


20 compound of formula (17)



using a reagent R^2L , as described above for the production of a

25 compound of formula (5) from a compound of formula (15).


Intermediates of formula (17) may be obtained from the corresponding protected compounds of formula (18)



wherein X¹ is a protected hydroxy, thio, amino or aldehyde group using conventional deprotection procedures [see Green, T. W. *ibid*]. Thus for example where X¹ is a t-butyldimethylsilyloxy group, the required hydroxyl group may be obtained by treatment of the protected intermediate with tetra-butylammonium fluoride. In another example where X¹ is a dioxanyl group, the required aldehyde group may be obtained by acid hydrolysis of the protected intermediate with trifluoroacetic acid or p-toluene sulphonic acid, in the presence of a solvent, e.g. acetone, or a mixture of solvents, e.g. chloroform and water.

The protected intermediates of formula (18) may be prepared in an analogous manner to the compounds of formula (1) using the reactions described herein and appropriately protected intermediates.

In a further aspect of the invention, compounds of general formula (1) where X is a chain -C(R)=C(Rᵇ)-, in which R is a hydrogen atom or a methyl group, may be prepared by coupling a compound of formula (19)



where R is as defined above with an olefination agent

Particular examples of olefination agents include phosphonium salts such as compounds (Rᵇ)(R²)CHP(D)₃Hal where Hal is a halogen atom, such as a bromine atom, and D is an optionally substituted alkyl, e.g. methyl, or aryl, especially phenyl, group; phosphoranes (Rᵇ)(R²)C=P(D)₃;

phosphonates $(DO)_2P(O)CH(R^b)(R^2)$; or silane derivatives, for example compounds of formula $(D)_3SiC(R^5)(R^6)$, e.g. trialkylsilanes such as $(CH_3)_3SiC(R^b)(R^2)$.

- 5 Bases for use in the above reaction include organometallic bases, for example, an organolithium compound such as an alkyllithium e.g. n-butyllithium, a hydride, such as sodium or potassium hydride or an alkoxide, such as a sodium alkoxide, e.g. sodium methoxide.
- 10 The reaction may be performed in a suitable solvent, for example a polar aprotic solvent, such as an alkyl sulphoxide, e.g. methyl sulphoxide, an amide such as N,N-dimethylformamide or hexamethylphosphorous triamide; a non-polar solvent, such as an ether, e.g. tetrahydrofuran or diethyl ether or an aromatic solvent such as benzene, toluene or xylene; or
- 15 a polar protic solvent, such as an alcohol, for example ethanol. Preferably the reaction is carried out at a low temperature, for example from around $-78^\circ C$ to around room temperature.

The olefination agents used in this reaction are either known compounds

20 or may be prepared from known starting materials using reagents and conditions similar to those used to prepare the known compounds. For example, a phosphorane may be prepared in situ by reaction of a phosphonium salt with a base of the type described above. In another example, a phosphonate may be prepared by reacting a halide

25 $(R^b)(R^2)CHHal$ with a phosphite $(DO)_3P$, as described in the Arbuzov reaction. Silane derivatives may be prepared by reaction of a halosilane $(D)_3SiHal$ with a base, such as lithium diisopropylamide, in a solvent, such as an ether, for example a cyclic ether, e.g. tetrahydrofuran, at low temperature, e.g. $-10^\circ C$.


30

According to a further aspect of the invention compounds of formula (1) where X is a group $-C(R)=CH(R^b)$ and R^2 is an optionally substituted alkyl, alkenyl or alkynyl group may also be prepared by reaction of an intermediate of formula (19) with an organometallic reagent, for example

35 as described above in connection with the preparation of intermediates of formula (4), followed by dehydration of the corresponding alcohol. The


dehydration may be performed using an acid, for example an organic acid such as p-toluene sulphonic acid or trifluoroacetic acid, in the presence of a base, such as an amine, e.g. triethylamine.

- 5 Intermediates of formula (19) may be prepared by deprotecting an intermediate of formula (20)




- 10 where X¹ is an aldehyde or ketone protecting group.

Intermediates of formula (20) may be prepared by reaction of a compound of formula (21)




- 15 with an organometallic reagent or a halide in an analogous manner to the preparation of intermediates of formula (4) from intermediates of formula (5)

- 20 Intermediates of formula (21) may be prepared by oxidation of an alcohol of formula (22)



- 25 using an oxidising agent, such as manganese (IV) oxide, in a solvent, such as dichloromethane, at room temperature.


Intermediates of formula (22) may be prepared by reaction of a halide of formula (23)



5

with an aldehyde $R^4\text{CHO}$, in the presence of a base, such as n-butyllithium, in a solvent, e.g. tetrahydrofuran, at a temperature from around -70°C to room temperature.

- 10 Intermediates of formula (23) may be prepared by protecting an aldehyde of formula (24)




using the reagents and conditions described herein above.

15

Intermediates of formula (24) are either known compounds or may be prepared in a similar manner to the known compounds.


- 20 In another aspect of the invention, a compound a formula (1) in which $=W-$ is a $=C(X^aR^1)-$ group in which X^a is $-O-$ may be prepared by alkylating an intermediate of formula (25)



using a reagent R^1L where L is a leaving group as described above.

The reaction may be performed using the reagents and conditions described above for the production of a compound of formula (5) from a
5 compound of formula (15).


Intermediates of formula (25) where R^3 is propen-2-yl may be prepared in a Claisen rearrangement by heating an allylic aryl ether of formula (26)



at elevated temperature.

Intermediates of formula (23) may be prepared by reacting an intermediate
15 of formula (4) where W is a $=C(OCH_3)-$ group with a thiol reagent, such as propanethiol, in the presence of a base, such as a hydride, e.g. sodium or potassium hydride, or an amide, e.g. sodium bis (trimethylsilyl)amide. The reaction may be performed in a solvent, such as dimethylformamide at an
20 elevated temperature, e.g. the reflux temperature.

Intermediates of formula (25) may also be prepared by deprotecting a compound of formula (26)



where X^2 is a protected hydroxyl group, e.g. methoxy, using iodotrimethylsilane in chloroform.

Intermediates of formula (24) may be prepared using similar protected reagents and conditions to those used for the preparation of intermediates of formula (4).

5 Compounds of formula (1) may also be prepared by interconversion of other compounds of formula (1). These reactions will generally involve the group R^{13} , whether present as the group R^3 or as a substituent on a group Ar in R^4 or R^6 . Thus, in one example of an interconversion process a compound of formula (1) which contains a $-CH_2NH_2$ substituent may be
10 prepared by reduction of a corresponding compound of formula (1) which contains a nitrile group, using for example a complex metal hydride such as lithium aluminium hydride in a solvent such as an ether e.g. diethylether.

15 In a further example, a compound of formula (1) with an alkanoylamino or alkanoylaminoalkyl substituent may be prepared by acylation of a corresponding compound of formula (1) containing a $-NH_2$ or alkylamino group by reaction with an acyl halide in the presence of a base, such as a tertiary amine e.g. triethylamine in a solvent such as dichloromethane.

20 Compounds of formula (1) where X is a chain $[-CH(R)]_q-CH(R^b)-$ may be prepared by hydrogenation of a compound of formula (1) where X is a chain $-C(R)=C(R^b)-$ using the reagents and conditions described above for the production of a compound of formula (1) from an intermediate of
25 formula (13).

In yet another example of an interconversion process, compounds of formula (1) containing an ester $[CO_2Alk^2]$, e.g. an ethanoate, may be prepared by esterification of a corresponding compound of formula (1)
30 containing a carboxylic acid, using an acid halide, such as an acid chloride, e.g. acetyl chloride, in an alcohol, such as ethanol, at an elevated temperature, such as the reflux temperature.

Compounds of formula (1) containing a carboxylic acid may be prepared
35 from the corresponding compound of formula (1) containing a formyl

group, by oxidation with an oxidising agent, e.g. potassium permanganate, in a solvent, such as an alcohol, e.g. tert-butanol, at ambient temperature.

5 In a further interconversion reaction, compounds of formula (1) which contain an aminoalkyl group, such as dimethylaminomethyl, may be prepared by reductive amination of a corresponding compound of formula (1) which contains a formyl group, using an amine, e.g. dimethylamine, in the presence of a reducing agent, e.g. sodium cyanoborohydride, if necessary in the presence of a catalyst, e.g. ethanolic HCl, in a solvent, 10 such as an alcohol, e.g. methanol, at ambient temperature.

In another example of an interconversion reaction a compound of formula (1) which contains a formyl group, may be reduced to the corresponding alcohol, using a reducing agent, e.g. sodium borohydride, in a solvent, 15 such as an alcohol, e.g. ethanol, at a temperature from around 0°C to ambient temperature. The resulting alcohol may then be converted to a corresponding alkoxy derivative, e.g. methoxymethyl, by reaction with an alkyl halide or alkyl sulphonate using the methods and reagents described above for the alkylation of intermediates of formula (9).

20 In a further example of an interconversion process compounds of formula (1) which contain a carboxamido (-CONHAlk¹) or an aminocarbonyl (-NHCOAlk¹) group may be prepared by reaction of the corresponding compound containing a -CO₂H or a -NH₂ group respectively by reaction 25 with a carbamate, such as i-butyl chloroformate or ethyl chloroformate, in the presence of a base, such as an amine, e.g. triethylamine or N-methylmorpholine, in a solvent, such as dichloromethane, or a mixture of solvents, e.g. tetrahydrofuran and dimethylformamide, at a temperature from around -20°C to room temperature.

30 In a still further interconversion reaction, compounds of formula (1) which contain a -NHCONHAlk¹ group may be prepared by reacting a corresponding compound of formula (1) which contains an amino (-NH₂) group, with an isocyanate, e.g. ethyl isocyanate, in a solvent, e.g. 35 dichloromethane, at ambient temperature.

In another example of an interconversion process, compounds of formula (1) wherein R^7 is an alkyl group, may be prepared by interconversion of a compound of formula (1) where R^7 is a hydrogen atom by reaction with a compound R^7L , where L is a leaving group, for example a halogen atom, such as chlorine, in the presence of a base, for example lithium diisopropylamide, in a solvent such as tetrahydrofuran, at low temperature, such as 0°C.

Compounds of formula (1) wherein R^5 is an OR^c group where R^c is an alkyl, alkoxyalkyl, formyl or alkanoyl group, may be prepared in another example of an interconversion process by reaction of a compound of formula (1) where R^5 is a -OH group with a compound R^cL (where R^c is as just defined and L is a leaving group as described above), in a solvent, such as dichloromethane or tetrahydrofuran in the presence of a base, for example triethylamine or potassium tert-butoxide, at room temperature.

In a further interconversion process compounds of formula (1) wherein R^c is a carboxamido (-CONHAlk¹) or a thiocarboxamido (-CSNHAlk¹) group, may be prepared by reaction of a compound of formula (1) wherein R^5 is a hydroxyl group with an isocyanate Alk¹NCO or an isothiocyanate Alk¹NCS, in a solvent, for example chloroform, in the presence of a base, for example diisopropylethylamine, at ambient temperature. The isocyanate Alk¹NCO and isothiocyanate Alk¹NCS are known compounds or may be prepared in a conventional manner.

In a further example, a compound of formula (1) wherein R^c is a CON[Alk¹]₂ group may be prepared by reaction of a compound of formula (1) wherein R^c is a CONHAlk¹ group with a reagent Alk¹L (where L is a leaving group as described above) in the presence of a base, for example sodium hydride, in a solvent, such as tetrahydrofuran, at low temperature, for example 0°C.

In another example, an isothiocyanate of formula (1) where R^c is -CSN[Alk¹]₂ may be prepared by reacting a compound of formula (1) wherein R^c is a -CON[Alk¹]₂ group with a thiation reagent, such as

Lawesson's Reagent, in an anhydrous solvent, for example toluene, at elevated temperature, such as the reflux temperature.

5 N-oxides of compounds of formula (1) may be prepared for example by oxidation of the corresponding nitrogen base using an oxidising agent such as hydrogen peroxide in the presence of an acid such as acetic acid, at an elevated temperature, for example around 70°C to 80°C, or alternatively by reaction with a peracid such as peracetic acid in a solvent, e.g. dichloromethane, at ambient temperature.

10 Salts of compounds of formula (1) may be prepared by reaction of a compound of formula (1) with an appropriate acid or base in a suitable solvent or mixture of solvents e.g. an organic solvent such as an ether e.g. diethylether, or an alcohol, e.g. ethanol using conventional procedures.

15 Where it is desired to obtain a particular enantiomer of a compound of formula (1) this may be produced from a corresponding mixture of enantiomers using any suitable conventional procedure for resolving enantiomers.

20 Thus for example diastereomeric derivatives, e.g. salts, may be produced by reaction of a mixture of enantiomers of formula (1) e.g. a racemate, and an appropriate chiral compound, e.g. a chiral acid or base. Suitable chiral acids include, for example, tartaric acid and other tartrates such as
25 dibenzoyl tartrates and ditoluoyl tartrates, sulphonates such as camphor sulphonates, mandelic acid and other mandelates and phosphates such as 1,1'-binaphthalene-2,2'-diyl hydrogen phosphate. The diastereomers may then be separated by any convenient means, for example by crystallisation and the desired enantiomer recovered, e.g. by treatment
30 with an acid or base in the instance where the diastereomer is a salt.

In another resolution process a racemate of formula (1) may be separated using chiral High Performance Liquid Chromatography .

Alternatively, if desired a particular enantiomer may be obtained by using an appropriate chiral intermediate in one of the processes described above.

- 5 The following examples illustrate the invention. The following abbreviations are used: DMF - dimethylformamide; THF - tetrahydrofuran; DME - dimethoxyethane; EtOAc - ethyl acetate; Et₂O - diethyl ether; Et₃N - triethylamine; BuLi - butyllithium; LDA - lithium diisopropylamide; EtOH - ethanol; CHCl₃ - chloroform; CH₂Cl₂ -
10 dichloromethane; MeOH - methanol; RT - room temperature.

All ¹Hnmr spectra were obtained at 300MHz unless specified otherwise.

INTERMEDIATE 1

15 3-Cyclopentyloxy-4-methoxybenzaldehyde

The title compound was prepared as described for Intermediate 9 in International Patent Specification No. WO 94/14742.

INTERMEDIATE 2

20 (±)-4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-hydroxyethyl]pyridine

The title compound was prepared as described in Example 2b) in International Patent Specification No. WO 94/20446.

INTERMEDIATE 3

25 (E)-4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)ethenyl]pyridine

The title compound was prepared as described for Intermediate 5c) in International Patent Specification No. WO 94/20446.

INTERMEDIATE 4

30 4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)ethyl]pyridine

The title compound was prepared as described in Example 3f) in International Patent Specification No. WO 94/20446.

INTERMEDIATE 5

35 (R)-(+)-4-[2-(3-Hydroxy-4-methoxyphenyl)-2-phenylethyl]pyridine

To a stirred solution of NaH (60% dispersion in mineral oil) (0.483g, 12.075mmol) in DMF under nitrogen at RT was added propanethiol (1.09ml, 12.07mmol) and the mixture stirred for 30min. A solution of (R)-(+)-4-[2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine (made as described in WO 94/14742) (1.8g, 4.83mmol) in DMF was added, the mixture heated to reflux for 5h, allowed to cool (the reaction was followed by tlc) and concentrated *in vacuo*. The residue was taken up in CH₂Cl₂ and washed with aqueous NaHCO₃ solution. The aqueous phase was extracted with CH₂Cl₂, the combined organic phase dried (MgSO₄), filtered and concentrated *in vacuo*. The residue was subjected to chromatography (SiO₂; Et₂O) then recrystallised (i-propylether) to give the title compound (6.00g) as a white solid. m.p. 158-159°C. (Found C, 79.37; H, 6.96; N, 3.66. C₂₄H₂₅O₂N requires C, 80.19; H, 7.01; N, 3.90%). δ_H (CDCl₃) 1.5-1.9 (8H, m, (CH₂)₄), 3.39 (2H, dd, \downarrow 8, 1Hz, CH₂ pyridine), 4.12 (1H, t, \downarrow 8Hz, CHCH₂), 4.62 (1H, m, OCH), 5.52 (1H, br s, OH), 6.57 (1H, m, C₆H₃), 6.6-6.7 (1H, m, C₆H₃), 6.75-6.8 (1H, m, C₆H₃), 6.91 (2H, d, \downarrow 6.Hz, H₃, H₅ pyridine), 7.1-7.3 (5H, m, C₆H₅), and 8.38 (2H, d, \downarrow 6Hz, H₂, H₆ pyridine).

20 INTERMEDIATE 6

4-[2-(R)-(3-Cyclopentyloxy-4-prop-2-enyloxyphenyl)-2-phenylethyl]-pyridine hydrochloride

To a stirred solution of Intermediate 5 (2.031g, 5.66mmol) in THF (60ml) and DMF (20ml) at RT, under nitrogen, was added potassium t-butoxide (0.8g, 6.77mmol). After 20min, allyl bromide (0.56ml, 6.47mmol) was added, the mixture stirred at RT for 20min then quenched with water and extracted with EtOAc. The combined organic phase was dried (MgSO₄), filtered and concentrated *in vacuo* to give the title compound free base (2.2g) as a yellow gum.

30 A small amount of the free base was treated with ethereal HCl to give the title compound as an off-white solid (Found C, 71.18; H, 6.58; N, 2.93. C₂₇H₃₁NO₂Cl. H₂O requires C, 71.26; H, 6.86; N, 3.08%). m/z (ESI) (M⁺, 400, 100%). δ_H (CD₃OD) 1.05-1.85 (5H, m), 3.7 (2H, d, \downarrow 9.0Hz), 4.45-4.52 (3H, m), 4.7 (1H, m), 5.19 (1H, dd, \downarrow 3.01, 6.0Hz), 5.3 (1H, dd, \downarrow 3.0, 9.0Hz), 5.9-6.1 (1H, m), 6.7-6.82 (3H, m), 7.1-7.39 (5H, m), 7.82 (2H, d, \downarrow 6.0Hz) and 8.6 (2H, d, \downarrow 6.0Hz).

INTERMEDIATE 7**4-[2-(R)-[3-Cyclopentyloxy-4-hydroxy-5-prop-3-enylphenyl]-2-phenyl]ethylpyridine hydrochloride**

5 Intermediate 6 (2.2g, 5.51mmol) was heated in a silicon oil bath at 230°C for 2h under nitrogen. The crude product was subjected to chromatography (SiO₂; MeOH-CH₂Cl₂, 5:95) to give the free base (1.41g) as a yellow gum.

A small amount of the free base was treated with ethereal HCl to give the
10 title compound as an off-white solid. *m/z* (ESI) (M⁺H, 400, 50%) (Found C, 71.57; H, 6.58; N, 3.00. C₂₇H₃₀NO₂Cl requires C, 71.42; H, 6.66; N, 3.08%). δ_H (CD₃OD) 1.5-1.98 (5H, m), 3.3 (2H, dd, J 3.0, 6.0Hz), 3.68 (2H, dd, J 3.0, 6.0Hz), 3.7 (2H, dd, J 3.0, 6.0Hz), 4.32-4.45 (1H, m), 4.78 (1H, m), 4.9 (2H, dd, J 3.0, 9.0Hz under HOD), 5.8-6.0 (1H, m), 6.6
15 (2H, dd, J 3.0, 30Hz), 7.1-7.4 (5H, m), 7.81 (2H, d, J 3.0Hz) and 8.6 (2H, d, J 3.0Hz).

EXAMPLE 1**a) 4-[2-(5-Cyclopentyloxy-2-iodo-4-methoxyphenyl)ethyl]pyridine**

20 Silver triflate (2.57g, 10.0mmol) was added to a solution of Intermediate 4 (3.00g, 10.0mmol) in CHCl₃ (100ml) at RT. A solution of iodine (2.54g, 10.0mmol) in CHCl₃ (100ml) was added dropwise and the mixture allowed to stir for a further 1h at RT. Sodium thiosulphate solution (100ml) was added and the organic layer separated and combined with a CH₂Cl₂
25 portion (50ml). The extract was dried (MgSO₄) and concentrated *in vacuo*. The residue was subjected to chromatography (SiO₂; Et₂O) to afford the title compound (3.89g) as a pale yellow solid; δ_H (CDCl₃) 1.4-1.9 (8H, br m, (CH₂)₄), 2.8-3.0 (4H, m, CH₂CH₂ pyridine), 3.81 (3H, s, OMe), 4.60 (1H, br m, OCH), 6.55 (1H, s, ArH *meta* to methoxy), 7.12
30 (2H, dd, J 4.5, 1.5 Hz, pyridine H₃, H₅), 7.22 (1H, s, ArH *ortho* to methoxy), and 8.50 (2H, dd, J 4.5, 1.5 Hz, pyridine H₂, H₆).

The following compound was prepared in a manner similar to the compound of Example 1a):

35 b) **(R)-4-[2-(3-Cyclopentyloxy-6-iodo-4-methoxyphenyl)-2-phenyl-ethyl]pyridine**

From (R)-(+)-4-[2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine (made as described in International Patent Specification No. WO 94/14742) (1.82g, 4.88mmol) in CHCl_3 (50ml)m, silver triflate (1.26g, 4.88mmol) and iodine (1.24g, 4.88mmol). Chromatography (SiO_2 ; EtOAc) afforded the title compound (2.2g) as a colourless gum. (Found C, 59.23; H, 5.32; N, 2.67. $\text{C}_{23}\text{H}_{26}\text{NO}_2$ requires C, 60.13; H, 5.25; N, 2.81) δ_{H} (CDCl_3) 1.5-1.9 (8H, m, CH_2), 3.25 (1H, d, \downarrow 5Hz, CH_2 pyridine), 3.27 (1H, d, \downarrow 5Hz, CH_2 pyridine), 3.74 (3H, s, OCH_3), 4.6-4.7 (1H, m, OCH), 4.64 (1H, t, \downarrow 8Hz, CH phenyl), 6.74 (1H, s, C_6H_2), 7.01 (2H, d, \downarrow 5Hz, H_3 , H_5 pyridine), 7.24 (1H, s, C_6H_2), 7.25-7.4 (5H, m, C_6H_5), and 8.39 (2H, d, \downarrow 5Hz, H_2 , H_6 pyridine). m/z 500 (M^+ , 100%), 406 (25) and 212 (14).

EXAMPLE 2

4-[2-(5-Cyclopentyloxy-4-methoxy-2-phenyl)ethyl]pyridine

hydrochloride

A solution of the compound of Example 1 (1.06g, 2.5mmol) in dioxane (10ml) was added to a solution of tetrakis (triphenylphosphine)palladium (0.144g, 0.125mmol) in dioxane (20ml) and the mixture stirred at RT for 0.5h. Sodium carbonate solution (2M; 3.25ml) and phenylboronic acid (0.305g, 2.5mmol) were then added and the mixture heated to reflux for 16h. The cooled reaction mixture was poured into sodium hydrogen carbonate solution (20ml) and extracted with CH_2Cl_2 (2x25ml). The extract was dried (MgSO_4), concentrated *in vacuo*, and the residue subjected to chromatography (SiO_2 ; Et₂O) to afford the title compound free base.

The base was dissolved in Et₂O (20ml) and treated with ethanolic HCl to afford the title compound (320mg) as a pale yellow solid m.p. 179-180°C; δ_{H} (CDCl_3) 1.5-2.0 (8H, br m, $(\text{CH}_2)_4$), 2.6-2.7 (2H, m, CH_2CH_2), 2.8-2.9 (2H, m, CH_2CH_2), 3.80 (3H, s, OMe), 4.74 (1H, br m, OCH), 6.69 (1H, s, ArH ortho to alkoxy), 6.72 (1H, s, ArH ortho to alkoxy), 6.80 (2H, dd, \downarrow 4.5, 1.5 Hz, pyridine H_3 , H_5), 7.2-7.5 (5H, m, C_6H_5), and 8.37 (2H, dd, \downarrow 4.5, 1.5 Hz, pyridine H_2 , H_6); m/z (EI) 373 (M^+ , 12%) 305 (17), 182 (18), 181 (100), 153 (28), 152 (22), 94 (17), 93 (46), and 69 (23).

EXAMPLE 3

(E)- and (Z)-isomers of 4-[2-(5-Cyclopentyloxy-4-methoxy-2-(2-phenylethenyl))ethyl]pyridine

A mixture of the compound of Example 1 (1.27g, 3.0mmol), styrene (417mg, 4.0mmol), Et₃N (404mg, 4.0mmol), palladium (II) acetate (34mg, 0.15mmol), and tri-*n*-butylphosphine (41mg, 0.5mmol) in acetonitrile (5ml) was heated in a bomb at 140°C for 24h. The cooled reaction mixture was poured into sodium hydrogen carbonate solution (10ml) and extracted with CH₂Cl₂ (2x25ml). The extract was dried (MgSO₄), concentrated *in vacuo*, and the residue subjected to chromatography (SiO₂; Et₂O) to afford the title compound (1.05g) as a cream solid m.p. 91-94°C. δ_H (CDCl₃) 1.5-1.7 and 1.75-1.95 (8H, m, (CH₂)₄), 2.8-3.1 (4H, m, (CH₂)₂ pyridine), 3.90 (3H, s, OMe), 4.60-4.75 (1H, m, OCH), 6.51 (1H, s, ArH), 6.6-7.5 (8H, m, ArH + (CH)₂ + C₆H₅), 7.07 (2H, d, J 7.5Hz, H₃, H₅ pyridine), and 8.47 (2H, d, J 7.5 Hz, H₂, H₆ pyridine).

15

EXAMPLE 4

4-[2-(R)-[3-Cyclopentyloxy-4-methoxy-5-prop-3-enylphenyl]-2-phenyl]ethylpyridine

To a stirred solution of Intermediate 7 (243mg) in dry THF-DMF (8ml; 3:1) at RT was added potassium tert-butoxide (90mg). After 20 min, iodomethane (0.042ml) was added and the solution stirred a further 40-min, then quenched with H₂O. The reaction mixture was partitioned between H₂O-EtOAc and the aqueous phase extracted with EtOAc. The combined organic phase was dried (MgSO₄) then evaporated. Chromatography (SiO₂; EtOAc-hexane, 30-50%) afforded the title compound (0.167g) as a yellow oil. Found (C, 80.43; H, 7.52; N, 3.55. C₂₈H₃₁NO₂ requires C, 81.32; H, 7.56; N, 3.36%). δ_H (CDCl₃) 1.55-1.8 (8H, br m), 3.3 (4H, dd, J 6.0Hz), 3.61 (3H, s), 4.13 (1H, t, J 9.0Hz), 4.58 (1H, s), 4.92-5.08 (2H, m), 5.82-5.97 (1H, m), 6.6 (2H, dd, J 3.0, 6.0Hz), 6.92 (2H, d, J 6.0Hz), 7.15-7.3 (5H, m), 8.4 (2H, d, J 6.0Hz). m/z (ESI) 414 (M⁺H 414, 100%).

30

FORMULATION EXAMPLES

The compounds of the invention may be formulated for pharmaceutical use in a number of forms using any suitable excipients. Thus, for

35

example, for oral use the compounds of the invention such as the compounds of the Examples may be formulated as a solid dosage form, by mixing an appropriate weight of compound (for example 50mg) with maize starch (50-99%w/w), anhydrous colloidal silica (0-10%w/w) and organic or inorganic acid (up to 1%w/w), to fill capsules of an appropriate size, e.g. white opaque hard gelatine capsules size 3. If desired the same mixture may be compressed into tablets.

The activity and selectivity of compounds according to the invention was demonstrated in the following tests. In these tests the abbreviation FMLP represents the peptide N-formyl-met-leu-phe.

Isolated Enzyme

The potency and selectivity of the compounds of the invention was determined using distinct PDE isoenzymes as follows:

- i. PDE I, rabbit heart
- ii. PDE II, rabbit heart
- iii. PDE III, rabbit heart, Jurkat cells
- iv. PDE IV, HL60 cells, rabbit brain, rabbit kidney and human recombinant PDE IV
- v. PDE V, rabbit lung, guinea pig lung

A gene encoding human PDE IV has been cloned from human monocytes (Livi, *et al.*, 1990, *Molecular and Cellular Biology*, 10, 2678). Using similar procedures we have cloned human PDE IV genes from a number of sources including eosinophils, neutrophils, lymphocytes, monocytes, brain and neuronal tissues. These genes have been transfected into yeast using an inducible vector and various recombinant proteins have been expressed which have the biochemical characteristics of PDE IV (Beavo and Reifsnyder, 1990, *TIPS*, 11, 150). These recombinant enzymes, particularly the human eosinophil recombinant PDE IV, have been used as the basis of a screen for potent, selective PDE IV inhibitors.

The enzymes were purified to isoenzyme homogeneity using standard chromatographic techniques.

Phosphodiesterase activity was assayed as follows. The reaction was conducted in 150µl of standard mixture containing (final concentrations): 50mM 2-[[tris(hydroxymethyl)methyl]amino]-1-ethane-sulphonic acid (TES) -NaOH buffer (pH 7.5), 10mM MgCl₂, 0.1µM [³H]-cAMP and vehicle or various concentrations of the test compounds. The reaction was initiated by addition of enzyme and conducted at 30°C for between 5 to 30 mins. The reaction was terminated by addition of 50µl 2% trifluoroacetic acid containing [¹⁴C]-5'AMP for determining recovery of the product. An aliquot of the sample was then applied to a column of neutral alumina and the [³H]-cAMP eluted with 10ml 0.1 TES-NaOH buffer (pH8). The [³H]-5'-AMP product was eluted with 2ml 2M NaOH into a scintillation vial containing 10ml of scintillation cocktail. Recovery of [³H]-5'AMP was determined using the [¹⁴C]-5'AMP and all assays were conducted in the linear range of the reaction.

Compounds according to the invention such as the most potent compounds of the Examples herein cause a concentration-dependent inhibition of recombinant PDE IV at 0.1 - 1000nM with little or no activity against PDE I, II, III or V at concentrations up to 100µM.

2. The Elevation of cAMP in Leukocytes

The effect of compounds of the invention on intracellular cAMP was investigated using human neutrophils or guinea pig eosinophils. Human neutrophils were separated from peripheral blood, incubated with dihydrocytochalasin B and the test compound for 10 min and then stimulated with FMLP. Guinea pig eosinophils were harvested by peritoneal lavage of animals previously treated with intra-peritoneal injections of human serum. Eosinophils were separated from the peritoneal exudate and incubated with isoprenaline and test compound. With both cell types, suspensions were centrifuged at the end of the incubation, the cell pellets were resuspended in buffer and boiled for 10 min prior to measurement of cAMP by specific radioimmunoassay (DuPont).

The most potent compounds according to the Examples induced a concentration -dependent elevation of cAMP in neutrophils and/or eosinophils at concentrations of 0.1nM to 1µM.

5 3. **Suppression of Leukocyte Function**

10 Compounds of the invention were investigated for their effects on superoxide generation, chemotaxis and adhesion of neutrophils and eosinophils. Isolated leukocytes were incubated with dihydrocytochalasin B for superoxide generation only and test compound prior to stimulation with FMLP. The most potent compounds of the Examples caused a concentration-dependent inhibition of superoxide generation, chemotaxis and adhesion at concentrations of 0.1nM to 1µM.


15 Lipopolysaccharide (LPS)-induced synthesis of tumour necrosis factor (TNF) by human peripheral blood monocytes (PBM) is inhibited by compounds of the Examples at concentrations of 0.01nM to 10µM.

20 4. **Adverse Effects**

In general, in our tests above, compounds of the invention have had no observed toxic effects when administered to animals at pharmacologically effective doses.

CLAIMS

1. A compound of formula (1)



wherein

=W- is (1) =C(Y)- where Y is a halogen atom, or an alkyl, or -X^aR¹ group where X^a is -O-, -S(O)_m- [where m is zero or an integer of value 1 or 2], or -N(R^a)- [where R^a is a hydrogen atom or an optionally substituted alkyl group] and R¹ is an optionally substituted alkyl group or, (2) =N-;


X is as described above for X^a or is a chain -CR=C(R^b)- or -[CH(R)]_q-CH(R^b)- where R is a hydrogen or a fluorine atom or a methyl group, R^b is as described below for R² and q is zero or the integer 1;

R² is (1) an optionally substituted alkyl, alkenyl, cycloalkyl or cycloalkenyl group when X is -O-, -S(O)_m- or -N(R^a)-; or when X is -CR=C(R^b)- or -[CH(R)]_q-CH(R^b)- is (2) a hydrogen atom, or an optionally substituted straight or branched alkyl, alkenyl or alkynyl, alkoxy, alkylthio, -CO₂R⁹ (where R⁹ is a hydrogen atom or an optionally substituted alkyl, aryl or aralkyl group), -CONR¹⁰R¹¹ (where R¹⁰ and R¹¹ which may be the same or different is as described for R⁹), -CSNR¹⁰R¹¹, -CN or NO₂ group; or R² and R^b, together with the carbon atom to which they are both attached, are linked to form an optionally substituted cycloalkyl or cycloalkenyl group optionally containing one or more X^a atoms or groups;

R³ is an atom or group R¹³ or -L¹R¹³ where L¹ is a linker group and R¹³ is a halogen atom or an Alk¹ [where Alk¹ is an optionally substituted straight or branched C₁₋₆ alkyl, C₂₋₆alkenyl or C₂₋₆alkynyl group optionally interrupted by one, two, or three -O-, or -S- atoms or -S(O)_p-, [where p is an integer 1 or 2], or -N(R^a)- groups], or an amino (-NH₂), substituted amino, nitro, cyano, hydroxyl (-OH),

substituted hydroxyl, cycloalkyl, cycloalkoxy, formyl [HC(O)-],
 carboxyl (-CO₂H), esterified carboxyl, thiol (-SH), substituted thiol,
 -C(O)Alk¹, -SO₃H, -SO₂Alk¹, -SO₂NH₂, -SO₂NHAlk¹, -SO₂N[Alk¹]₂,
 -SO₂NHAr [where Ar is as defined below for R⁶], -SO₂N(Alk¹)Ar,
 5 -CONH₂, -CONHAlk¹, -CON[Alk¹]₂, -CONHAr, -CON(Alk¹)Ar,
 -NHSO₂H, -NAlk¹SO₂H, -NHSO₂Alk¹, -NAlk¹SO₂Alk¹,
 -N[SO₂Alk¹]₂, -N(Alk¹)SO₂N(Alk¹)Ar, -NHSO₂NH₂,
 -N(Alk¹)SO₂NH₂, -NHSO₂NHAlk¹, -N(Alk¹)SO₂NHAlk¹,
 -NHSO₂N[Alk¹]₂, -NAlk¹SO₂N[Alk¹]₂, -NHSO₂NHAr,
 10 -N(Alk¹)SO₂NHAr, -NHSO₂N(Alk¹)Ar, -N(Alk¹)SO₂N(Alk¹)Ar,
 -NHC(O)Alk¹, -N(Alk¹)C(O)Alk¹, -N[C(O)Alk¹]₂, -NHC(O)OAlk¹,
 -N(Alk¹)C(O)OAlk¹, -Ar, -Het [where Het is a C₅₋₇ heterocycloalkyl
 group], -CONHet¹ [where -NHet¹ is a C₅₋₇ cycloamino group
 optionally containing one or more -O- or -S- atoms or -N(R^a)-
 15 groups], -SO₂NHet¹, -NHSO₂NHet¹, -CSAlk¹, -CSNH₂, -CSNAlk¹,
 -CSN[Alk¹]₂, -CSNHAr, -CSN(Alk¹)Ar, -NHC(S)Alk¹,
 -N(Alk¹)C(S)Alk¹, -CSNHet¹ group, -N[C(S)Alk¹]₂,
 -N[C(O)Alk¹]SO₂Alk¹, -N[C(S)Alk¹]SO₂Alk¹, -NHC(O)NH₂,
 -NHC(O)NHAlk¹, -NHC(O)N[Alk¹]₂, -N(Alk¹)CONH₂,
 20 -N(Alk¹)C(O)NHAlk¹, -N(Alk¹)C(O)N[Alk¹]₂, -NHC(S)NH₂,
 -NHC(S)NHAlk¹, -NHC(S)N[Alk¹]₂, -N(Alk¹)CSNH₂,
 -N(Alk¹)C(S)NHAlk¹, or -N(Alk¹)C(S)N[Alk¹]₂, group;
 R⁴ is a hydrogen atom or is as defined for R⁶;
 R⁵ is a hydrogen or a fluorine atom, or an OR^c group where R^c is a
 25 hydrogen atom or an optionally substituted straight or branched alkyl,
 alkenyl, alkoxyalkyl, alkanoyl, formyl, carboxamido, thiocarboxamido,
 cycloalkyl, or cycloalkenyl group;
 R⁶ is a group -(CH₂)_nAr where Ar is an optionally substituted
 monocyclic or bicyclic aryl ring optionally interrupted by one or more
 30 heteroatoms -O-, -S- or -N- and n is zero or the integer 1, 2 or 3;
 R⁷ and R⁸, which may be the same or different, is a hydrogen or a
 fluorine atom, or an optionally substituted straight or branched alkyl
 group;
 and the salts, solvates, prodrugs, hydrates and N-oxides thereof.

2. A compound according to Claim 1 wherein =W- is =C(X^aR¹)- and X is -O-, -S(O)_m- or -N(R^a)-.
3. A compound according to Claim 1 or Claim 2 wherein R² is an optionally substituted cyclopentyl group.
4. A compound according to Claims 1 to 3 wherein R⁵, R⁷ and R⁸ is each a hydrogen atom.
5. A compound according to Claims 1 to 4 wherein R⁴ is a hydrogen atom or a phenyl or substituted phenyl group.
6. A compound according to Claims 1 to 5 wherein R⁶ is an optionally substituted pyridyl group.
7. A compound according to any of the preceding claims wherein R³ is a halogen atom, or an alkyl, alkenyl, alkynyl, aryl, aralkyl, aralkenyl, heteroaryl or heteroaralkyl group.
8. A compound which is:
 - 4-[2-(5-Cyclopentyloxy-2-iodo-4-methoxyphenyl)ethyl]pyridine;
 - 4-[2-(5-Cyclopentyloxy-4-methoxy-2-phenyl)ethyl]pyridine;
 - 4-{2-[5-Cyclopentyloxy-4-methoxy-2-(2-phenylethenyl)phenyl]ethyl}pyridine;
 - 4-{2-[5-Cyclopentyloxy-4-methoxy-2-(2-phenylethyl)phenyl]ethyl}pyridine;
 - 4-{2-[5-Cyclopentyloxy-4-methoxy-2-(1-naphthyl)phenyl]ethyl}pyridine;
 - 4-{2-[5-Cyclopentyloxy-4-methoxy-2-(2-naphthyl)phenyl]ethyl}pyridine;
 - 4-{2-[5-Cyclopentyloxy-4-methoxy-2-(3-pyridyl)phenyl]ethyl}pyridine;
 - or each isomer or enantiomer, and/or the salts, hydrates, solvates, prodrugs and N-oxides thereof.
9. A pharmaceutical composition comprising a compound of formula (1)



wherein

=W- is (1) =C(Y)- where Y is a halogen atom, or an alkyl, or -X^aR¹ group where X^a is -O-, -S(O)_m- [where m is zero or an integer of value 1 or 2], or -N(R^a)- [where R^a is a hydrogen atom or an optionally substituted alkyl group] and R¹ is an optionally substituted alkyl group or, (2) =N-;


X is as described above for X^a or is a chain -CR=C(R^b)- or -[CH(R)]_q-CH(R^b)- where R is a hydrogen or a fluorine atom or a methyl group, R^b is as described below for R² and q is zero or the integer 1;

R² is (1) an optionally substituted alkyl, alkenyl, cycloalkyl or cycloalkenyl group when X is -O-, -S(O)_m- or -N(R^a)-; or when X is -CR=C(R^b)- or -[CH(R)]_q-CH(R^b)- is (2) a hydrogen atom, or an optionally substituted straight or branched alkyl, alkenyl or alkynyl, alkoxy, alkylthio, -CO₂R⁹ (where R⁹ is a hydrogen atom or an optionally substituted alkyl, aryl or aralkyl group), -CONR¹⁰R¹¹ (where R¹⁰ and R¹¹ which may be the same or different is as described for R⁹), -CSNR¹⁰R¹¹, -CN or NO₂ group; or R² and R^b, together with the carbon atom to which they are both attached, are linked to form an optionally substituted cycloalkyl or cycloalkenyl group optionally containing one or more X^a atoms or groups;

R³ is an atom or group R¹³ or -L¹R¹³ where L¹ is a linker group and R¹³ is a halogen atom or an Alk¹ [where Alk¹ is an optionally substituted straight or branched C₁₋₆ alkyl, C₂₋₆alkenyl or C₂₋₆alkynyl group optionally interrupted by one, two, or three -O-, or -S- atoms or -S(O)_p-, [where p is an integer 1 or 2], or -N(R^a)- groups], or an amino (-NH₂), substituted amino, nitro, cyano, hydroxyl (-OH), substituted hydroxyl, cycloalkyl, cycloalkoxy, formyl [HC(O)-], carboxyl (-CO₂H), esterified carboxyl, thiol (-SH), substituted thiol, -C(O)Alk¹, -SO₃H, -SO₂Alk¹, -SO₂NH₂, -SO₂NHAlk¹, -SO₂N[Alk¹]₂, -SO₂NHAr [where Ar is as defined below for R⁶], -SO₂N(Alk¹)Ar,

- CONH₂, -CONHAlk¹, -CON[Alk¹]₂, -CONHAr, -CON(Alk¹)Ar,
 -NHSO₂H, -NAlk¹SO₂H, -NHSO₂Alk¹, -NAlk¹SO₂Alk¹,
 -N[SO₂Alk¹]₂, -N(Alk¹)SO₂N(Alk¹)Ar, -NHSO₂NH₂,
 -N(Alk¹)SO₂NH₂, -NHSO₂NHAlk¹, -N(Alk¹)SO₂NHAlk¹,
 5 -NHSO₂N[Alk¹]₂, -NAlk¹SO₂N[Alk¹]₂, -NHSO₂NHAr,
 -N(Alk¹)SO₂NHAr, -NHSO₂N(Alk¹)Ar, -N(Alk¹)SO₂N(Alk¹)Ar,
 -NHC(O)Alk¹, -N(Alk¹)C(O)Alk¹, -N[C(O)Alk¹]₂, -NHC(O)OAlk¹,
 -N(Alk¹)C(O)OAlk¹, -Ar, -Het [where Het is a C₅₋₇ heterocycloalkyl
 group], -CONHet¹ [where -NHet¹ is a C₅₋₇ cycloamino group
 10 optionally containing one or more -O- or -S- atoms or -N(R^a)-
 groups], -SO₂NHet¹, -NHSO₂NHet¹, -CSAlk¹, -CSNH₂, -CSNHAlk¹,
 -CSN[Alk¹]₂, -CSNHAr, -CSN(Alk¹)Ar, -NHC(S)Alk¹,
 -N(Alk¹)C(S)Alk¹, -CSNHet¹ group, -N[C(S)Alk¹]₂,
 -N[C(O)Alk¹]SO₂Alk¹, -N[C(S)Alk¹]SO₂Alk¹, -NHC(O)NH₂,
 15 -NHC(O)NHAlk¹, -NHC(O)N[Alk¹]₂, -N(Alk¹)CONH₂,
 -N(Alk¹)C(O)NHAlk¹, -N(Alk¹)C(O)N[Alk¹]₂, -NHC(S)NH₂,
 -NHC(S)NHAlk¹, -NHC(S)N[Alk¹]₂, -N(Alk¹)CSNH₂,
 -N(Alk¹)C(S)NHAlk¹, or -N(Alk¹)C(S)N[Alk¹]₂ group;
 R⁴ is a hydrogen atom or is as defined for R⁶;
 20 R⁵ is a hydrogen or a fluorine atom, or an OR^c group where R^c is a
 hydrogen atom or an optionally substituted straight or branched alkyl,
 alkenyl, alkoxyalkyl, alkanoyl, formyl, carboxamido, thiocarboxamido,
 cycloalkyl, or cycloalkenyl group;
 R⁶ is a group -(CH₂)_nAr where Ar is an optionally substituted
 25 monocyclic or bicyclic aryl ring optionally interrupted by one or more
 heteroatoms -O-, -S- or -N- and n is zero or the integer 1, 2 or 3;
 R⁷ and R⁸, which may be the same or different, is a hydrogen or a
 fluorine atom, or an optionally substituted straight or branched alkyl
 group;
 30 and the salts, solvates, prodrugs, hydrates and N-oxides thereof.

10. A process for the preparation of a compound of formula (1)



wherein


=W- is (1) =C(Y)- where Y is a halogen atom, or an alkyl, or -X^aR¹ group where X^a is -O-, -S(O)_m- [where m is zero or an integer of value 1 or 2], or -N(R^a)- [where R^a is a hydrogen atom or an optionally substituted alkyl group] and R¹ is an optionally substituted alkyl group or, (2) =N-;

X is as described above for X^a or is a chain -CR=C(R^b)- or -[-CH(R)]_q-CH(R^b)- where R is a hydrogen or a fluorine atom or a methyl group, R^b is as described below for R² and q is zero or the integer 1;

R² is (1) an optionally substituted alkyl, alkenyl, cycloalkyl or cycloalkenyl group when X is -O-, -S(O)_m- or -N(R^a)-; or when X is -CR=C(R^b)- or -[-CH(R)]_q-CH(R^b)- is (2) a hydrogen atom, or an optionally substituted straight or branched alkyl, alkenyl or alkynyl, alkoxy, alkylthio, -CO₂R⁹ (where R⁹ is a hydrogen atom or an optionally substituted alkyl, aryl or aralkyl group), -CONR¹⁰R¹¹ (where R¹⁰ and R¹¹ which may be the same or different is as described for R⁹), -CSNR¹⁰R¹¹, -CN or NO₂ group; or R² and R^b, together with the carbon atom to which they are both attached, are linked to form an optionally substituted cycloalkyl or cycloalkenyl group optionally containing one or more X^a atoms or groups;


R³ is an atom or group R¹³ or -L¹R¹³ where L¹ is a linker group and R¹³ is a halogen atom or an Alk¹ [where Alk¹ is an optionally substituted straight or branched C₁₋₆ alkyl, C₂₋₆alkenyl or C₂₋₆alkynyl group optionally interrupted by one, two, or three -O-, or -S- atoms or -S(O)_p-, [where p is an integer 1 or 2], or -N(R^a)- groups], or an amino (-NH₂), substituted amino, nitro, cyano, hydroxyl (-OH), substituted hydroxyl, cycloalkyl, cycloalkoxy, formyl [HC(O)-], carboxyl (-CO₂H), esterified carboxyl, thiol (-SH), substituted thiol, -C(O)Alk¹, -SO₃H, -SO₂Alk¹, -SO₂NH₂, -SO₂NHAlk¹, -SO₂N[Alk¹]₂, -SO₂NHAr [where Ar is as defined below for R⁶], -SO₂N(Alk¹)Ar,

- CONH₂, -CONHAlk¹, -CON[Alk¹]₂, -CONHAr, -CON(Alk¹)Ar,
 -NHSO₂H, -NAlk¹SO₂H, -NHSO₂Alk¹, -NAlk¹SO₂Alk¹,
 -N[SO₂Alk¹]₂, -N(Alk¹)SO₂N(Alk¹)Ar, -NHSO₂NH₂,
 -N(Alk¹)SO₂NH₂, -NHSO₂NHAlk¹, -N(Alk¹)SO₂NHAlk¹,
 5 -NHSO₂N[Alk¹]₂, -NAlk¹SO₂N[Alk¹]₂, -NHSO₂NHAr,
 -N(Alk¹)SO₂NHAr, -NHSO₂N(Alk¹)Ar, -N(Alk¹)SO₂N(Alk¹)Ar,
 -NHC(O)Alk¹, -N(Alk¹)C(O)Alk¹, -N[C(O)Alk¹]₂, -NHC(O)OAlk¹,
 -N(Alk¹)C(O)OAlk¹, -Ar, -Het [where Het is a C₅₋₇ heterocycloalkyl
 group], -CONHet¹ [where -NHet¹ is a C₅₋₇ cycloamino group
 10 optionally containing one or more -O- or -S- atoms or -N(R^a)-
 groups], -SO₂NHet¹, -NHSO₂NHet¹, -CSAlk¹, -CSNH₂, -CSNHAlk¹,
 -CSN[Alk¹]₂, -CSNHAr, -CSN(Alk¹)Ar, -NHC(S)Alk¹,
 -N(Alk¹)C(S)Alk¹, -CSNHet¹ group, -N[C(S)Alk¹]₂,
 -N[C(O)Alk¹]SO₂Alk¹, -N[C(S)Alk¹]SO₂Alk¹, -NHC(O)NH₂,
 15 -NHC(O)NHAlk¹, -NHC(O)N[Alk¹]₂, -N(Alk¹)CONH₂,
 -N(Alk¹)C(O)NHAlk¹, -N(Alk¹)C(O)N[Alk¹]₂, -NHC(S)NH₂,
 -NHC(S)NHAlk¹, -NHC(S)N[Alk¹]₂, -N(Alk¹)CSNH₂,
 -N(Alk¹)C(S)NHAlk¹, or -N(Alk¹)C(S)N[Alk¹]₂ group;
 R⁴ is a hydrogen atom or is as defined for R⁶;
 20 R⁵ is a hydrogen or a fluorine atom, or an OR^c group where R^c is a
 hydrogen atom or an optionally substituted straight or branched alkyl,
 alkenyl, alkoxyalkyl, alkanoyl, formyl, carboxamido, thiocarboxamido,
 cycloalkyl, or cycloalkenyl group;
 R⁶ is a group -(CH₂)_nAr where Ar is an optionally substituted
 25 monocyclic or bicyclic aryl ring optionally interrupted by one or more
 heteroatoms -O-, -S- or -N- and n is zero or the integer 1, 2 or 3;
 R⁷ and R⁸, which may be the same or different, is a hydrogen or a
 fluorine atom, or an optionally substituted straight or branched alkyl
 group;
 30 and the salts, solvates, prodrugs, hydrates and N-oxides thereof.
 which comprises in a final step
 a) cross-coupling an intermediate of formula (3)




where Hal is an iodine or bromine atom
 with a coupling reagent to give a compound of formula (1) where R³
 is a group L¹R¹³;

b) hydrogenation of a compound of formula (16)




to give a compound of formula (1) wherein R⁸ and R⁵ is each a
 hydrogen atom;

c) alkylation of a compound of formula (17)




where X is -O-, -S- or -N(Rᵃ)-
 with a reagent R²L where L is a leaving group;

d) coupling an intermediate of formula (19)




wherein R is a hydrogen atom or a methyl group;
 with an olefination agent to give a compound of formula (1) wherein X
 5 is a chain $-C(R)=C(R^b)-$ in which R is a hydrogen atom or a methyl
 group.

e) alkylation of a compound of formula (25)



with a reagent R^1L where L is a leaving group to give a compound of
 formula (1) in which $=W-$ is $=C(OR^1)-$;

15 f) halogenation of a compound of formula (4)



to give a compound of formula (1) where R^3 is a halogen atom; or
 20

g) interconverting a compound of formula (1) to another
 compound of formula (1)

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 95/01467

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07D213/30 A61K31/44

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	WO,A,95 04045 (RHONE-POULENC RORER LIMITED) 9 February 1995 see Ref. examples see claims 1,29-38 ---	1,9,10
A	WO,A,94 10118 (CELLTECH LIMITED) 11 May 1994 see the whole document ---	1-10
A	TRENDS IN PHARMACOLOGICAL SCIENCES, vol.11, 1990, CAMBRIDGE GB pages 150 - 155 J.A. BEAVO ET AL. 'Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors.' cited in the application see the whole document ---	1,9
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

25 September 1995

Date of mailing of the international search report

- 5. 10. 95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Bosma, P

INTERNATIONAL SEARCH REPORT

Int. .onal Application No

PCT/GB 95/01467

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>TRENDS IN PHARMACOLOGICAL SCIENCES, vol.12, 1991, CAMBRIDGE GB pages 19 - 27 C.D NICHOLSON ET AL. 'Different modulation of tissue function and therapeutic optential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes.' cited in the application see the whole document -----</p>	1,9

INTERNATIONAL SEARCH REPORT

ernational application No.

PCT/GB95/01467

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
The subject matter of the present claims 1-5,7,9 and 10 is so broad that a complete search is not possible on economic grounds (PCT Search Guidelines III, 3.6 and 3.7). Therefore the search has been based on the examples and the claims as indicated. (Claims 1-5,7,9,10 have been searched incompletely).
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

information on patent family members

Int. onal Application No

PCT/GB 95/01467

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9504045	09-02-95	AU-B- 7267094	28-02-95

WO-A-9410118	11-05-94	AU-B- 5340894	24-05-94
		CA-A- 2126072	11-05-94
		EP-A- 0618889	12-10-94
		JP-T- 7502762	23-03-95
